Literature DB >> 28676533

Kisspeptin-10 inhibits OHSS by suppressing VEGF secretion.

Junyu Zhai1,2, Jiansheng Liu1,2, Shigang Zhao3, Han Zhao3, Zi-Jiang Chen1,2,3, Yanzhi Du4,2, Weiping Li4,2.   

Abstract

The aim of the present study was to elucidate the effects of kisspeptin-10 (Kp-10) on ovarian hyperstimulation syndrome (OHSS) and its related mechanism in OHSS rat models, human umbilical vein endothelial cells (HUVECs) and human luteinized granulosa cells. OHSS is a systemic disorder with high vascular permeability (VP) and ovarian enlargement. KISS1R (KISS1 receptor) is the specific receptor of kisspeptin. The kisspeptin/KISS1R system inhibits the expression of vascular endothelial growth factor (VEGF), which is the main regulator of VP. In our study, decreased expression of Kiss1r was observed in both ovaries and lung tissue of OHSS rats. Injection of exogenous Kp-10 inhibited the increase of VP and VEGF while promoting the expression of Kiss1r in both the ovarian and lung tissue of OHSS rats. Using HUVECs, we revealed that a high level of 17-β estradiol (E2), a feature of OHSS, suppressed the expression of KISS1R and increased VEGF and nitric oxide (NO) through estrogen receptors (ESR2). Furthermore, KISS1R mRNA also decreased in the luteinized human granulosa cells of high-risk OHSS patients, and was consistent with the results in rat models and HUVECs. In conclusion, Kp-10 prevents the increased VP of OHSS by the activation of KISS1R and the inhibition of VEGF.
© 2017 Society for Reproduction and Fertility.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28676533     DOI: 10.1530/REP-17-0268

Source DB:  PubMed          Journal:  Reproduction        ISSN: 1470-1626            Impact factor:   3.906


  10 in total

Review 1.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

2.  Rare genetic variants suggest dysregulation of signaling pathways in low- and high-risk patients developing severe ovarian hyperstimulation syndrome.

Authors:  L Borgwardt; K W Olsen; M Rossing; R Borup Helweg-Larsen; M Toftager; A Pinborg; J Bogstad; K Løssl; A Zedeler; M L Grøndahl
Journal:  J Assist Reprod Genet       Date:  2020-09-18       Impact factor: 3.412

Review 3.  From inhibition of trophoblast cell invasion to proapoptosis: what are the potential roles of kisspeptins in preeclampsia?

Authors:  Viviane C L Gomes; Jenny L Sones
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-05-19       Impact factor: 3.210

Review 4.  Kisspeptin/Kisspeptin Receptor System in the Ovary.

Authors:  Kai-Lun Hu; Hongcui Zhao; Hsun-Ming Chang; Yang Yu; Jie Qiao
Journal:  Front Endocrinol (Lausanne)       Date:  2018-01-04       Impact factor: 5.555

5.  Nintedanib Treatment After Ovulation is an Effective Therapeutic Strategy for the Alleviation of Ovarian Hyperstimulation Syndrome (OHSS) in a Mouse Model.

Authors:  Shutian Jiang; Wenzhi Li; Xinxi Zhao; Li Chen; Yanping Kuang
Journal:  Drug Des Devel Ther       Date:  2022-02-18       Impact factor: 4.162

Review 6.  The role of Kisspeptin signaling in Oocyte maturation.

Authors:  Saeed Masumi; Eun Bee Lee; Iman Dilower; Sameer Upadhyaya; V Praveen Chakravarthi; Patrick E Fields; M A Karim Rumi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-22       Impact factor: 6.055

Review 7.  Use of kisspeptin to trigger oocyte maturation during in vitro fertilisation (IVF) treatment.

Authors:  Bhavna Sharma; Kanyada Koysombat; Alexander N Comninos; Waljit S Dhillo; Ali Abbara
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-06       Impact factor: 6.055

8.  Follicle Size on Day of Trigger Most Likely to Yield a Mature Oocyte.

Authors:  Ali Abbara; Lan N Vuong; Vu N A Ho; Sophie A Clarke; Lisa Jeffers; Alexander N Comninos; Rehan Salim; Tuong M Ho; Tom W Kelsey; Geoffrey H Trew; Peter Humaidan; Waljit S Dhillo
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-25       Impact factor: 5.555

9.  Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment.

Authors:  A Abbara; R Islam; S A Clarke; L Jeffers; G Christopoulos; A N Comninos; R Salim; S A Lavery; T N L Vuong; P Humaidan; T W Kelsey; G H Trew; W S Dhillo
Journal:  Clin Endocrinol (Oxf)       Date:  2018-03-06       Impact factor: 3.478

10.  Expression of the anti-Mullerian hormone, kisspeptin 1, and kisspeptin 1 receptor in polycystic ovary syndrome and controlled ovarian stimulation rat models.

Authors:  Ali Risvanli; Halis Ocal; Necati Timurkaan; Pinar Ipek; Ibrahim Seker; Burak Karabulut
Journal:  Bosn J Basic Med Sci       Date:  2020-02-05       Impact factor: 3.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.